Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Payables (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Payables for 4 consecutive years, with $943000.0 as the latest value for Q4 2025.

  • Quarterly Payables fell 27.18% to $943000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $943000.0 through Dec 2025, down 27.18% year-over-year, with the annual reading at $943000.0 for FY2025, 27.18% down from the prior year.
  • Payables for Q4 2025 was $943000.0 at Spruce Biosciences, down from $1.4 million in the prior quarter.
  • The five-year high for Payables was $3.4 million in Q1 2023, with the low at $682000.0 in Q2 2024.
  • Average Payables over 4 years is $1.7 million, with a median of $1.4 million recorded in 2022.
  • The sharpest move saw Payables surged 210.91% in 2023, then plummeted 61.13% in 2024.
  • Over 4 years, Payables stood at $1.4 million in 2022, then soared by 133.66% to $3.3 million in 2023, then tumbled by 61.13% to $1.3 million in 2024, then fell by 27.18% to $943000.0 in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $943000.0, $1.4 million, and $807000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.